Clinical impact of rapid bacterial microbiological identification with the MALDI-TOF MS

Uzuriaga, Miriam; Leiva, José; Guillén Grima, Francisco; Rua, Marta; Yuste, José R.

Publication:
Clinical impact of rapid bacterial microbiological identification with the MALDI-TOF MS

dc.contributor.author	Uzuriaga, Miriam
dc.contributor.author	Leiva, José
dc.contributor.author	Guillén Grima, Francisco
dc.contributor.author	Rua, Marta
dc.contributor.author	Yuste, José R.
dc.contributor.department	Ciencias de la Salud	es_ES
dc.contributor.department	Osasun Zientziak	eu
dc.date.accessioned	2024-05-07T16:53:24Z
dc.date.available	2024-05-07T16:53:24Z
dc.date.issued	2023
dc.date.updated	2024-05-07T16:30:02Z
dc.description.abstract	Rapid microbiological reports to clinicians are related to improved clinical outcomes. We conducted a 3-year quasi-experimental design, specifically a pretest–posttest single group design in a university medical center, to evaluate the clinical impact of rapid microbiological identification information using MALDI-TOF MS on optimizing antibiotic prescription. A total of 363 consecutive hospitalized patients with bacterial infections were evaluated comparing a historical control group (CG) (n = 183), in which the microbiological information (bacterial identification and antibiotic susceptibility) was reported jointly to the clinician between 18:00 h and 22:00 h of the same day and a prospective intervention group (IG) (n = 180); the bacterial identification information was informed to the clinician as soon as it was available between 12:00 h and 14:00 h and the antibiotic susceptibility between 18:00 h and 22:00 h). We observed, in favor of IG, a statistically significant decrease in the information time (11.44 h CG vs. 4.48 h IG (p < 0.01)) from the detection of bacterial growth in the culture medium to the communication of identification. Consequently, the therapeutic optimization was improved by introducing new antibiotics in the 10–24 h time window (p = 0.05) and conversion to oral route (p = 0.01). Additionally, we observed a non-statistically significant decrease in inpatient mortality (global, p = 0.15; infection-related, p = 0.21) without impact on hospital length of stay. In conclusion, the rapid communication of microbiological identification to clinicians reduced reporting time and was associated with early optimization of antibiotic prescribing without worsening clinical outcomes.	en
dc.description.sponsorship	This work was supported by bioMérieux (Marcy l’Etoile, France).	en
dc.format.mimetype	application/pdf	en
dc.identifier.citation	Uzuriaga, M., Leiva, J., Guillén-Grima, F., Rua, M., Yuste, J. R. (2023) Clinical impact of rapid bacterial microbiological identification with the MALDI-TOF MS. Antibiotics, 12(12), 1-13. https://doi.org/10.3390/antibiotics12121660.	en
dc.identifier.doi	10.3390/antibiotics12121660
dc.identifier.issn	2079-6382
dc.identifier.uri	https://academica-e.unavarra.es/handle/2454/48058
dc.language.iso	eng	en
dc.publisher	MDPI	en
dc.relation.ispartof	Antibiotics 2023, 12(12), 1660	en
dc.relation.publisherversion	https://doi.org/10.3390/antibiotics12121660
dc.rights	© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.	en
dc.rights.accessRights	info:eu-repo/semantics/openAccess
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.subject	Antibiotic use	en
dc.subject	Clinical impact	en
dc.subject	Diagnostics	en
dc.subject	MALDI-TOF MS	en
dc.subject	Quick information	en
dc.title	Clinical impact of rapid bacterial microbiological identification with the MALDI-TOF MS	en
dc.type	info:eu-repo/semantics/article
dc.type.version	Versión publicada / Argitaratu den bertsioa	es
dc.type.version	info:eu-repo/semantics/publishedVersion	en
dspace.entity.type	Publication
relation.isAuthorOfPublication	dfbf180f-dd66-42b9-ba45-2de0b3a334d5
relation.isAuthorOfPublication.latestForDiscovery	dfbf180f-dd66-42b9-ba45-2de0b3a334d5